Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules Sixth agreement signed under ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

Novo Nordisk has paid $60 million to partner Valo Health on a project that will apply the US start-up’s artificial intelligence-powered drug discovery engine to find new therapies for ...

CAMBRIDGE, Mass. & LEXINGTON, Mass., March 18, 2025--(BUSINESS WIRE)--Valo Health, Inc. ("Valo"), a biotechnology company focused on transforming the drug discovery and development process using ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for autoimmune diseases. The collaboration between Pfizer and Pioneering Medicines, ...

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today ...